Vanguard Group’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Vanguard Group’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,169,984	Closed	-$72.7M	–	4522
2023 Q4	$72.7M	Buy	1,169,984 +1,119,984	+2,240%	+$27.8M	﹤0.01%	2020
2023 Q3	$1.11M	Buy	+50,000	New	+$1.05M	﹤0.01%	3797

Vanguard Group's RYZB Position: Q1 2024 in Review

Vanguard Group sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 1,169,984 shares — an estimated $72.7M sold.

Vanguard Group first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $72.7M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Vanguard Group reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Vanguard Group sold 1,169,984 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $72.7M.
Vanguard Group first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Vanguard Group's RayzeBio, Inc. Common Stock position peaked at $72.7M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.